Skip to main content
. 2019 Feb 1;37(8):613–623. doi: 10.1200/JCO.18.00899

FIG 2.

FIG 2.

Progression-free survival (PFS) on the basis of derived independent review committee time point assessment (intent-to-treat population). Median PFS was 115 days for the alisertib arm versus 104 days for the comparator arm (hazard ratio, 0.87; 95% CI, 0.637 to 1.178).